tiprankstipranks
Advertisement
Advertisement

PCGONDO Stock Latest News

GondolaBio Highlights Patient-Focused FD/MAS Research Engagement
Private CompaniesGondolaBio Highlights Patient-Focused FD/MAS Research Engagement
3m ago
GONDO
GondolaBio Highlights Focus on Charcot-Marie-Tooth Awareness and Research
PremiumPrivate Companies
GondolaBio Highlights Focus on Charcot-Marie-Tooth Awareness and Research
7d ago
GONDO
GondolaBio Engages Rare Disease Community at 2026 Dup15q & Angelman Conference
PremiumPrivate Companies
GondolaBio Engages Rare Disease Community at 2026 Dup15q & Angelman Conference
27d ago
GONDO
GondolaBio Highlights Patient-Centric Focus in Rare Disease Efforts
PremiumPrivate Companies
GondolaBio Highlights Patient-Centric Focus in Rare Disease Efforts
29d ago
GONDO
GondolaBio Highlights Engagement With Tuberous Sclerosis Community
PremiumPrivate Companies
GondolaBio Highlights Engagement With Tuberous Sclerosis Community
1M ago
GONDO
GondolaBio Deepens Rare Disease Community Engagement to Inform Future Research
PremiumPrivate CompaniesGondolaBio Deepens Rare Disease Community Engagement to Inform Future Research
1M ago
GONDO
Patient-Centric Engagement Highlights GondolaBio’s Focus on Rare Disease Communities
Premium
Private Companies
Patient-Centric Engagement Highlights GondolaBio’s Focus on Rare Disease Communities
1M ago
GONDO
GondolaBio Highlights Patient-Centric Engagement in Rare Disease Research
Premium
Private Companies
GondolaBio Highlights Patient-Centric Engagement in Rare Disease Research
1M ago
GONDO
GondolaBio Highlights Focus on EPP Patient Needs and Rare Disease Research
PremiumPrivate Companies
GondolaBio Highlights Focus on EPP Patient Needs and Rare Disease Research
2M ago
GONDO
GondolaBio Strengthens Engagement With NF1 Community at Children’s Tumor Foundation Summit
PremiumPrivate Companies
GondolaBio Strengthens Engagement With NF1 Community at Children’s Tumor Foundation Summit
2M ago
GONDO
GondolaBio Emphasizes Patient-Centric Strategy in Rare Genetic Diseases
PremiumPrivate Companies
GondolaBio Emphasizes Patient-Centric Strategy in Rare Genetic Diseases
2M ago
GONDO
GondolaBio Boosts PORT-77 Profile With Positive Phase 2a Data and Expanded Rare-Disease Outreach
PremiumPrivate Companies
GondolaBio Boosts PORT-77 Profile With Positive Phase 2a Data and Expanded Rare-Disease Outreach
2M ago
GONDO
GondolaBio Highlights Positive Phase 2a Data for Rare-Disease Candidate PORT-77
PremiumPrivate CompaniesGondolaBio Highlights Positive Phase 2a Data for Rare-Disease Candidate PORT-77
3M ago
GONDO
GondolaBio Bolsters PORT-77 Visibility and Rare-Disease Community Ties in Busy Week
Premium
Private Companies
GondolaBio Bolsters PORT-77 Visibility and Rare-Disease Community Ties in Busy Week
3M ago
GONDO
Clinician Webinars Highlight Phase 2a Data and Plans for PORT-77 in Porphyria
Premium
Private Companies
Clinician Webinars Highlight Phase 2a Data and Plans for PORT-77 in Porphyria
3M ago
GONDO
GondolaBio Highlights Engagement With Alpha-1 Foundation Community
PremiumPrivate Companies
GondolaBio Highlights Engagement With Alpha-1 Foundation Community
3M ago
GONDO
GondolaBio Highlights Phase 2a PORT-77 Data and Development Plans in Porphyria
PremiumPrivate Companies
GondolaBio Highlights Phase 2a PORT-77 Data and Development Plans in Porphyria
3M ago
GONDO
GondolaBio – Weekly Recap
PremiumPrivate Companies
GondolaBio – Weekly Recap
3M ago
GONDO
GondolaBio Highlights Patient-Centric Engagement in NF-1 Research
PremiumPrivate Companies
GondolaBio Highlights Patient-Centric Engagement in NF-1 Research
3M ago
GONDO
Pipeline Progress Spotlight on PORT-77 Rare Disease Program
PremiumPrivate CompaniesPipeline Progress Spotlight on PORT-77 Rare Disease Program
3M ago
GONDO
GondolaBio – Weekly Recap
Premium
Private Companies
GondolaBio – Weekly Recap
3M ago
GONDO
Pipeline Progress Highlighted for PORT-77 in Rare Protoporphyria Indications
Premium
Private Companies
Pipeline Progress Highlighted for PORT-77 in Rare Protoporphyria Indications
3M ago
GONDO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >